Aceclofenac/Citronellol Nanoemulsion Inhibition of Melanoma Cell Lines: Formulation and Evaluation

Paul Hapau^*
*Correspondence: Paul Hapau, Department of Formulation, University of Economic Studies, Bucharest, Romania, Email:

Introduction

Melanoma, a type of skin cancer that originates from melanocytes, is notorious for its aggressiveness and high metastatic potential. Despite advancements in treatment, the incidence of melanoma continues to rise, making it a significant public health concern. Traditional cancer therapies often come with severe side effects, and there is an ongoing search for novel therapeutic approaches that can effectively target melanoma cells while minimizing adverse effects. One promising avenue of research in cancer therapy is nanotechnology, specifically the use of nanoemulsions for drug delivery. Nanoemulsions are colloidal systems with droplet sizes typically ranging from 20 to 200 nanometers, which can encapsulate both hydrophobic and hydrophilic compounds. This article explores the formulation and evaluation of an Aceclofenac/Citronellol nanoemulsion for the inhibition of melanoma cell lines, shedding light on the potential of nanoemulsions in cancer therapy. Aceclofenac is a Nonsteroidal Anti-Inflammatory Drug (NSAID) known for its anti-inflammatory and analgesic properties. Recent studies have shown that NSAIDs like Aceclofenac may possess anti-cancer properties by inhibiting the growth and proliferation of cancer cells. Citronellol, on the other hand, is a natural monoterpene alcohol found in essential oils. It has demonstrated anticancer activity by inducing apoptosis and inhibiting cell migration in various cancer types, including melanoma [1].

Description

The combination of Aceclofenac and Citronellol in a nanoemulsion represents a novel approach that capitalizes on their respective anticancer properties. Nanoemulsions have several advantages for drug delivery, such as improved solubility, stability, and enhanced cellular uptake. Moreover, the nanoscale droplet size of the emulsion allows for more efficient penetration into cancer cells, making it an ideal platform for delivering these therapeutic compounds. Formulating a stable and effective nanoemulsion is a critical step in developing a potential anticancer therapy. The formulation process involves selecting suitable components and optimizing their proportions. Here, we outline the key components and steps involved in the formulation of the Aceclofenac/Citronellol nanoemulsion. The hydrophobic drug is dissolved in the lipid phase. Aceclofenac serves as the core therapeutic component. Lipids such as soybean lecithin and CapryolTM 90 are used to stabilize the emulsion. Citronellol, being hydrophilic, is dissolved in the aqueous phase. Excipients like Tween 80 and PEG 400 are used to enhance the emulsion's stability and solubility [2].

The lipid and aqueous phases are homogenized using high-shear equipment to create a stable nanoemulsion. The homogenization process reduces droplet size and ensures uniform dispersion of the drug and Citronellol. The resulting nanoemulsion is characterized for parameters such as droplet size, polydispersity index, zeta potential, and drug encapsulation efficiency. These factors are crucial for determining the stability and effectiveness of the formulation. Once the nanoemulsion is formulated, it is essential to evaluate its potential as an anticancer agent. The evaluation involves in vitro studies using melanoma cell lines to assess its cytotoxicity and anti-proliferative effects. Various assays such as the MTT assay or the Alamar Blue assay can be performed to determine the cytotoxicity of the nanoemulsion. These assays measure cell viability and can help establish the concentration at which the nanoemulsion is toxic to melanoma cells [3].

To determine if the nanoemulsion induces apoptosis in melanoma cells, assays like flow cytometry or TUNEL staining can be employed. Apoptosis is a programmed cell death process often disrupted in cancer cells, so inducing apoptosis is a desirable outcome in cancer therapy. Melanoma's aggressiveness is often characterized by its ability to migrate and invade surrounding tissues. Inhibition of cell migration can be assessed through wound healing assays or Transwell migration assays. To gain insights into the molecular mechanisms underlying the anticancer effects of the nanoemulsion, Western blotting or RTqPCR can be performed to analyze changes in gene expression and protein levels in melanoma cells. Melanoma, a type of skin cancer that originates in melanocytes, is one of the deadliest forms of cancer. The rapid proliferation of melanoma cells and their ability to metastasize to other organs make it a significant public health concern. Current treatment options include surgery, chemotherapy, radiation therapy, and immunotherapy [4].

However, these treatments often come with side effects and may not be effective in all cases. Thus, there is a growing need for innovative and effective therapies to combat melanoma. In recent years, nanotechnology has emerged as a promising approach to develop targeted and efficient treatments for various cancers, including melanoma. In this article, we explore the formulation and evaluation of Aceclofenac/Citronellol nanoemulsion for the inhibition of melanoma cell lines [5].

Conclusion

The formulation and evaluation of Aceclofenac/Citronellol nanoemulsion for the inhibition of melanoma cell lines represent a promising step towards developing a novel and effective approach to melanoma therapy. The synergy between Aceclofenac's anti-inflammatory properties and Citronellol's anticancer effects, combined with the advantages of nanoemulsion drug delivery, holds great potential for improving the treatment outcomes of melanoma patients. Further research is needed to fine-tune the formulation and optimize dosages, as well as to conduct in vivo studies to assess the nanoemulsion's efficacy and safety. If successful, this approach may not only offer a more targeted and efficient treatment for melanoma but also pave the way for the development of nanoemulsion-based therapies for various other types of cancer. Ultimately, the combination of nanotechnology and innovative drug formulations may hold the key to a brighter future in the battle against cancer.

The development of innovative and effective therapies for melanoma is crucial to improve patient outcomes and reduce the burden of this deadly disease. Nanoemulsions, such as the Aceclofenac/Citronellol nanoemulsion, hold great promise in providing targeted and efficient treatment options for melanoma. Formulating and evaluating such nanoemulsions requires careful consideration of components, stability, and efficacy through in vitro and in vivo studies. If successful, these nanoemulsions could represent a significant advancement in melanoma therapy, offering improved therapeutic outcomes with reduced side effects. Further research and clinical trials are needed to validate their potential in clinical settings and bring hope to melanoma patients worldwide.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Younis, Mona K., Islam A. Khalil, Nancy S. Younis and Rasha R. Fakhr Eldeen, et al. "Aceclofenac/Citronellol oil nanoemulsion repurposing study: Formulation, in vitro characterization, and in silico evaluation of their antiproliferative and pro-apoptotic activity against melanoma cell line." Biomedicines 11 (2023): 2531.

   Google Scholar, Crossref, Indexed at

2. Rushing, Blake R. "Unlocking the molecular secrets of antifolate drug resistance: A multi-omics investigation of the NCI-60 cell line panel." Biomedicines 11 (2023): 2532.

   Google Scholar, Crossref, Indexed at

3. Hsieh, Ya-Chu, Yuan-Chang Dai, Kur-Ta Cheng and Wei-Ting Yang, et al. "Blockade of the SRC/STAT3/BCL-2 signaling axis sustains the cytotoxicity in human colorectal cancer cell lines induced by dehydroxyhispolon methyl ether." Biomedicines 11 (2023): 2530.

   Google Scholar, Crossref, Indexed at

4. Eustace, Alex J., John Crown, Martin Clynes and Norma O'Donovan. "Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines." J Transl Med 6 (2008): 1-11.

   Google Scholar, Crossref, Indexed at

5. Xiao, Jingjing, Michael E. Egger, Kelly M. McMasters and Hongying Hao. "Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines." BMC Cancer 18 (2018): 1-10.

   Google Scholar, Crossref, Indexed at